Functional nitric oxide conjugate systems state/restored heart thiols of rats in modeling isadrine-pituitrin’s myocardial infarction using metabolite-tropic cardioprotector “Angiolin”

Igor F. Belenichev, Lyudmila I. Kucherenko, Elena A. Nagornaya, Ivan A. Mazur, Alexander S. Bidnenko, Nina V. Bukhtiyarova, Nikolay A. Avramenko

Abstract


Background: According to modern researches, endothelial dysfunction (ED) is one of the primary pathogenetic elements of cardiovascular diseases (myocardial infarction [MI], ischemic heart diseases, cerebral ischemic stroke, atherosclerosis, arterial hypertension, pulmonary hypertension, heart failure, and dilated cardiomyopathy) as well as obesity, hyperlipidemia, diabetes and hyperhomocysteinemia. The aim of this work was to study the influence of potential metabolitotropic cardioprotector “Angiolin” on the parameters of conjugate systems nitric oxide (NO)/restored thiols in heart under isadrine-pituitrin MI.

Methods: This study was performed on Wistar white rats weighing 190-210 g. Biochemical, immune-enzyme analysis and histoimmunechemical study were performed.

Results: In histological sections of hearts of the rats receiving Angiolin in parenteral dosing 50 mg/kg 30 mins before each pituitrin injection the density of endothelial NO-synthase (NOS)-positive cells increased by 29% and the density of inducible NOS-positive cells decreased by 23.3%. In cytosolic fraction of myocardium homogenate NOS activity increased by 27%, the concentration of NO stable metabolites increased by 70% and the content of nitrosative stress marker nitrotyrosine decreased by 42% when compared with control group. At the same time in similar samples of heart homogenate the increase of restored thiol groups’ level by 53.3%, methionine - by 35.1%, cysteine - by 170% and activity of glutathione reductase - by 186% was noted. The administration of reference drug mildronate to the animals with MI in dose 100 mg/kg did not result in significant changes of the studied parameters of thiol-disulfide system and NO system of the heart when compared with control group.

Conclusions: Angiolin does not influence directly on NOS in MI, but at the same time protects NO from nitrosative stress increasing restored equivalents of thiol-disulfide system.


Keywords


Metabolitotropic cardioprotector, Angiolin, Myocardial infarction

Full Text:

PDF

References


Amosova EN. Metabolic therapy of myocardium damages caused by ischemia. New approach to the treatment of ischemic heart disease and heart failure. Ukr Cardiol J. 2000;4:86-92.

Belenichev IF, Bukhtiyarova NV. Mechanisms of ischemic neurodestruction formating: correlation of nitric oxide and thiol-disulfide system as the factor determining the fate of neurone. Int Neurol J. 2009;8(30):12-25.

Cardoni A, Pasini E. Insght into cytoprotection with metabolic agents. Eur Heart J. 1999;1:40-8.

Chekman IS, Gubskiy YUI, Gromov LA, Belenichev IF. Preclinical study of specific activity of potential neuroprotective preparations. Guidelines of State Pharmacological Center of the Ministry of Health of Ukraine. Kiev; 2010: 81.

Messerli FH, Mancia G, Conti CR, Pepine CJ. Guidelines on the management of stable angina pectoris: Executive summary: The task force on the management of stable angina pectoris of the European society of cardiology. Eur Heart J. 2006;27(23):2902-3.

Kalvinsh IYA. Mildronate: mode of action and prospects of its application. Riga; 2002.

Manukhina EB, Mashina SYu, Smirin BV, Lyamina NP, Senchikhin VN, Vanin AF, et al. Role of nitric oxide in adaptation to hypoxia and adaptive defense. Physiol Res. 2000;49(1):89-97.

Markov KHM. On bioregulatory system L-arginine - Nitric oxide. J Pathophysiol Exp Ther. 1996;1:34-6.

Mazur IA, Belenichev IF, Kolesnik YUM, Abramov AV, Kucherenko LI, Voloshyn MA, et al. Lizynium 3-methyl-1,2,4- triazolyl -5-thioacetate. Patent of Ukraine No. 86668. Date of Publication: 12.05.2009. IPC: C07D 249/08 (2006.01), A61K 31/4196 (2006.01), A61P 9/00, A61P 9/10 (2006.01), A61P 25/28 (2006.01). Available at http://www.base.uipv.org/searchINV/search.php?action=viewdetails&IdClaim=132048. Accessed 14 Oct 2014.

Mazur IA, Belenichev IF, Kolesnik YUM, Abramov AV, Kucherenko LI, Voloshyn MA, et al. Lysinium 3-methyl-1,2,4-triasolyl-5-thioacetate with neuroprotective, nootropic, cardioprotective, endotheliotropic, anti-ischemic, antioxidant, anti-inflammatory and antihypoxic effect and low toxicity. Patent of Russian Federation No. 2370492. Date of Publication: 20.10.2009. IPC: C07D249/12 (2006.01), A61K31/41 (2006.01). Available at http://www.fips.ru/cdfi/Fips2009.dll/CurrDoc?SessionKey=CZIQLPUDLR35SS7UV1DI&GotoDoc=1&Query=5. Accessed 14 Oct 2014.

Mazur IA, Chekman IS, Belenichev IF. Metabolitotropic drugs. Zaporozhye: Pechanty Mir; 2007: 309.

Mazur IA, Voloshin NA, Chekman IS. Thiotriazolin. Zaporozhye, Lvov: Nautilus; 2005: 156.

Mazur IA, Voloshin NA, Vizir VA, Belenichev IF. Thiotriazolin, thiodaron in treatment of cardiovascular pathology. Zaporozhye: Pechanty Mir; 2011: 303.

Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA. 1988;260(7):945-50.

Semigolovskiy Nyu, Kolbasov Syu, Lisitsyn DV. Rise of protective properties of mildronate. Vestnik of Saint Petersburg University. 2008;1:4-46.

Stefanov AV. Preclinical investigations of drugs. Kiev: Avicenna; 2002: 568.

Strick AT, Hogg N, Thomas JP. Nitric oxide donor compounds inhibit the toxicity of oxidized low-density lipoprotein to endothelian cells. FEBS Lett. 2005;361:291-4.

Vanin AF, Muller B, Alencar JL, Lobysheva II, Nepveu F, Stoclet JC. Evidence that intrinsic iron but not intrinsic copper determines S-nitrosocysteine decomposition in buffer solution. Nitric Oxide. 2002;7(3):194-209.

Vizir VA, Voloshin NA, Mazur IA, Belenichev IF. Metabolitotropic cardioprotectors. Zaporozhye: Pechanty Mir; 2006: 34.

Voloshin PV, Malakhov VA, Zavgoronyaya AN. Endothelial dysfunction in cerebrovascular pathology. Kharkov: KhMAPE; 2006: 94.